267 related articles for article (PubMed ID: 22449547)
41. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
42. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
43. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
44. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
45. 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.
Miyamoto H; Marwah P; Marwah A; Lardy H; Chang C
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4440-4. PubMed ID: 12672951
[TBL] [Abstract][Full Text] [Related]
46. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
Gaillard-Moguilewsky M
Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
[TBL] [Abstract][Full Text] [Related]
47. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.
Zhao XY; Boyle B; Krishnan AV; Navone NM; Peehl DM; Feldman D
J Urol; 1999 Dec; 162(6):2192-9. PubMed ID: 10569618
[TBL] [Abstract][Full Text] [Related]
48. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.
Attar RM; Jure-Kunkel M; Balog A; Cvijic ME; Dell-John J; Rizzo CA; Schweizer L; Spires TE; Platero JS; Obermeier M; Shan W; Salvati ME; Foster WR; Dinchuk J; Chen SJ; Vite G; Kramer R; Gottardis MM
Cancer Res; 2009 Aug; 69(16):6522-30. PubMed ID: 19654297
[TBL] [Abstract][Full Text] [Related]
49. Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
Koga H; Negishi M; Kinoshita M; Fujii S; Mori S; Ishigami-Yuasa M; Kawachi E; Kagechika H; Tanatani A
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759847
[TBL] [Abstract][Full Text] [Related]
50. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
[TBL] [Abstract][Full Text] [Related]
51. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
[TBL] [Abstract][Full Text] [Related]
52. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects.
Térouanne B; Tahiri B; Georget V; Belon C; Poujol N; Avances C; Orio F; Balaguer P; Sultan C
Mol Cell Endocrinol; 2000 Feb; 160(1-2):39-49. PubMed ID: 10715537
[TBL] [Abstract][Full Text] [Related]
53. Identification of steroid derivatives that function as potent antiandrogens.
Miyamoto H; Marwah P; Marwah A; Yang Z; Chung CY; Altuwaijri S; Chang C; Lardy H
Int J Cancer; 2005 Dec; 117(5):866-72. PubMed ID: 15981214
[TBL] [Abstract][Full Text] [Related]
54. Design and synthesis of novel androgen receptor antagonists via molecular modeling.
Zhao C; Choi YH; Khadka DB; Jin Y; Lee KY; Cho WJ
Bioorg Med Chem; 2016 Feb; 24(4):789-801. PubMed ID: 26780832
[TBL] [Abstract][Full Text] [Related]
55. Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile.
Hikichi Y; Yamaoka M; Kusaka M; Hara T
Eur J Pharmacol; 2015 Oct; 765():322-31. PubMed ID: 26335395
[TBL] [Abstract][Full Text] [Related]
56. Development of β-amino-carbonyl compounds as androgen receptor antagonists.
Zhang ZY; Zhu YH; Zhou CH; Liu Q; Lu HL; Ge YJ; Wang MW
Acta Pharmacol Sin; 2014 May; 35(5):664-73. PubMed ID: 24786235
[TBL] [Abstract][Full Text] [Related]
57. Antiandrogenic and apoptotic effects of RU-486 on animal prostate.
Cabeza M; Bratoeff E; Heuze I; Guzmán A; Gómez G; Berrios H; Rosales AM
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):321-5. PubMed ID: 17466516
[TBL] [Abstract][Full Text] [Related]
58. Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOP.
Kalach JJ; Joly-Pharaboz MO; Chantepie J; Nicolas B; Descotes F; Mauduit C; Benahmed M; André J
J Steroid Biochem Mol Biol; 2005 Jul; 96(2):119-29. PubMed ID: 15950459
[TBL] [Abstract][Full Text] [Related]
59. Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.
Suh JH; Chattopadhyay A; Sieglaff DH; Storer Samaniego C; Cox MB; Webb P
PLoS One; 2015; 10(9):e0137103. PubMed ID: 26332122
[TBL] [Abstract][Full Text] [Related]
60. Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor.
Lundqvist J; Tringali C; Oskarsson A
J Steroid Biochem Mol Biol; 2017 Nov; 174():161-168. PubMed ID: 28888979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
